Vivos Therapeutics, Inc.
VVOS Nasdaq
SEC CIK 1716166
Follow Vivos Therapeutics
Weekly email: filings, results
Revenue, last quarter
$6.4M
−5.4% vs same quarter last year
Net income
−$1.9M
+64% vs same quarter last year
EPS, diluted
−$0.07
+85.7% vs same quarter last year
Operating cash flow
−$3.2M
+23.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $17.4M | −$21.2M |
| FY24 | $15M | −$11.1M |
| FY23 | $13.8M | −$13.6M |
| FY22 | $16M | −$23.8M |
| FY21 | $16.9M | −$20.3M |
| FY20 | $13.1M | −$12.1M |
| FY19 | $11.4M | −$10.8M |
| FY18 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 60.4% | −114.1% | −121.7% |
| FY24 | 60% | −74.3% | −74.1% |
| FY23 | 59.9% | −125.3% | −98.4% |
| FY22 | 62.5% | −156.2% | −148.8% |
| FY21 | 74.6% | −120.7% | −120.2% |
| FY20 | 79.7% | −92.1% | −92.3% |
| FY19 | 76% | −92.8% | −94.4% |
| FY18 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$17.6M |
| FY24 | −$13.3M |
| FY23 | −$12.7M |
| FY22 | −$20.5M |
| FY21 | −$18.1M |
| FY20 | −$5.8M |
| FY19 | −$5.5M |
| FY18 | - |
- Vivos Therapeutics
- Healthcare median
Show the numbers
| Year | Vivos Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −121.7% | −30.6% |
| FY24 | −74.1% | −47% |
| FY23 | −98.4% | −58% |
| FY22 | −148.8% | −80.4% |
| FY21 | −120.2% | −71.9% |
| FY20 | −92.3% | −62.2% |
| FY19 | −94.4% | −46.3% |
| FY18 | - | −49.6% |